Paracetamol: New vistas of an old drug

被引:458
作者
Bertolini, Alfio
Ferrari, Anna
Ottani, Alessandra
Guerzoni, Simona
Tacchi, Raffaella
Leone, Sheila
机构
[1] Univ Modena & Reggio Emilia, Policlin Modena, Div Clin Pharmacol & Toxicol, I-41100 Modena, Italy
[2] Univ Modena & Reggio Emilia, Dept Biomed Sci, Pharmacol Sect, I-41100 Modena, Italy
[3] Univ G DAnnunzio, Sect Pharmacol & Pharmacognosy, Dept Pharmacol Sci, Chieti, Italy
来源
CNS DRUG REVIEWS | 2006年 / 12卷 / 3-4期
关键词
acetaminophen; cannabinoids; CB1; receptors; centrally acting analgersics; paracetamol;
D O I
10.1111/j.1527-3458.2006.00250.x
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Paracetamol (acetaminophen) is one of the most popular and widely used drugs for the treatment of pain and fever. It occupies a unique position among analgesic drugs. Unlike NSAIDs it is almost unanimously considered to have no antinflammatory activity and does not produce gastrointestinal damage or untoward cardiorenal effects. Unlike opiates it is almost ineffective in intense pain and has no depressant effect on respiration. Although paracetamol has been used clinically for more than a century, its mode of action has been a mystery until about one year ago, when two independent groups (Zygmunt and colleagues and Bertolini and colleagues) produced experimental data unequivocally demonstrating that the analgesic effect of paracetamol is due to the indirect activation of cannabinoid CBI receptors. In brain and spinal cord, paracetamol, following deacetylation to its primary amine (p-aminophenol), is conjugated with arachidonic acid to form N-arachidonoylphenolamine, a compound already known (AM404) as an endogenous cannabinoid. The involved enzyme is fatty acid amide hydrolase. N-arachidonoylphenolamine is an agonist at TRPV1 receptors and an inhibitor of cellular anandamide uptake, which leads to increased levels of endogenous cannabinoids; moreover, it inhibits cyclooxygenases in the brain, albeit at concentrations that are probably not attainable with analgesic doses of paracetamol. CB1 receptor antagonist, at a dose level that completely prevents the analgesic activity of a selective CB1 receptor agonist, completely prevents the analgesic activity of paracetamol. Thus, paracetamol acts as a pro-drug, the active one being a cannabinoid. These findings finally explain the mechanism of action of paracetamol and the peculiarity of its effects, including the behavioral ones. Curiously, just when the first CB I agonists are being introduced for pain treatment, it comes out that an indirect cannabinomimetic had been extensively used (and sometimes overused) for more than a century.
引用
收藏
页码:250 / 275
页数:26
相关论文
共 235 条
[1]   C-FOS EXPRESSION IN RAT LUMBAR SPINAL-CORD DURING THE DEVELOPMENT OF ADJUVANT-INDUCED ARTHRITIS [J].
ABBADIE, C ;
BESSON, JM .
NEUROSCIENCE, 1992, 48 (04) :985-993
[2]   CHRONIC TREATMENTS WITH ASPIRIN OR ACETAMINOPHEN REDUCE BOTH THE DEVELOPMENT OF POLYARTHRITIS AND FOS-LIKE IMMUNOREACTIVITY IN RAT LUMBAR SPINAL-CORD [J].
ABBADIE, C ;
BESSON, JM .
PAIN, 1994, 57 (01) :45-54
[3]   Phenacetin, acetaminophen and dipyrone: analgesic and rewarding effects [J].
Abbott, FV ;
Hellemans, KGC .
BEHAVIOURAL BRAIN RESEARCH, 2000, 112 (1-2) :177-186
[4]   Chapter 4 - European guidelines for the management of chronic nonspecific low back pain [J].
Airaksinen, O. ;
Brox, J. I. ;
Cedraschi, C. ;
Hildebrandt, J. ;
Klaber-Moffett, J. ;
Kovacs, F. ;
Mannion, A. F. ;
Reis, S. ;
Staal, J. B. ;
Ursin, H. ;
Zanoli, G. .
EUROPEAN SPINE JOURNAL, 2006, 15 (Suppl 2) :S192-S300
[5]   PHARMACOKINETICS OF ORALLY-ADMINISTERED ACETAMINOPHEN IN MAN [J].
ALBERT, KS ;
SEDMAN, AJ ;
WAGNER, JG .
JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1974, 2 (05) :381-393
[6]  
ANDERSON BJ, 1995, PAEDIATR ANAESTH, V5, P237
[7]   Paracetamol plasma and cerebrospinal fluid pharmacokinetics in children [J].
Anderson, BJ ;
Holford, NHG ;
Woollard, GA ;
Chan, PLS .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 46 (03) :237-243
[8]   Perioperative pharmacodynamics of acetaminophen analgesia in children [J].
Anderson, BJ ;
Holford, NHG ;
Woollard, GA ;
Kanagasundaram, S ;
Mahadevan, M .
ANESTHESIOLOGY, 1999, 90 (02) :411-421
[9]  
ANDERSON BJ, 1998, PAEDIATR ANAESTH, V8, P324
[10]  
ANDERSON RJ, 1976, CLIN USE DRUGS RENAL, P213